Liu P, Zhang H M, Tang Y J, Sheng C F, Liu J X, Zeng Y J
Bratisl Lek Listy. 2015;116(3):150-3. doi: 10.4149/bll_2015_030.
To investigate the influence of Fasudil, a Rho inhibitor on the number and functions of the late endothelial progenitor cells in peripheral blood of chronic obstructive pulmonary diseases (COPD) patients with pulmonary artery hypertension.
It is not clear yet, whether Rho Kinase Inhibitor Fasudil can reduced pulmonary artery pressure through improving lung endothelial function.
80 COPD patients with pulmonary artery hypertension were selected and divided into two groups: the treatment group and the control group, which had 40 patients, respectively. Changes in the number and function of the late endothelial progenitor cells in peripheral blood of the patients before and after the treatment were compared between the two groups. The changes on the pulmonary artery pressure were also compared.
The number of the late endothelial progenitor cells in peripheral blood of the treatment group increased and the function was enhanced. The pulmonary artery pressure was reduced. The difference before and after the treatment and with the control group was statistically significant (p < 0.05).
The Rho-kinase inhibitor Fasudil increased the number and enhanced the function of the late endothelial progenitor cells in peripheral blood of COPD patients with pulmonary artery hypertension (Tab. 3, Fig. 2, Ref. 17).
探讨Rho抑制剂法舒地尔对慢性阻塞性肺疾病（COPD）合并肺动脉高压患者外周血晚期内皮祖细胞数量及功能的影响。
Rho激酶抑制剂法舒地尔是否能通过改善肺内皮功能降低肺动脉压尚不清楚。
选取80例COPD合并肺动脉高压患者，分为治疗组和对照组，每组40例。比较两组患者治疗前后外周血晚期内皮祖细胞数量及功能的变化。同时比较肺动脉压的变化。
治疗组外周血晚期内皮祖细胞数量增加，功能增强，肺动脉压降低。治疗前后及与对照组比较差异有统计学意义（p<0.05）。
Rho激酶抑制剂法舒地尔可增加COPD合并肺动脉高压患者外周血晚期内皮祖细胞数量并增强其功能（表3，图2，参考文献17）。
